MOHINI HEALTH AND HYGIENE LTD (MHHL): Financials & Fundamentals History

Share Price

₹26.95

ROCE

-4.0%

Market Cap

₹49 cr

Revenue (TTM)

₹144 cr

P/S

0.3x

P/B

0.6x

ROE

-18.9%

Debt / Equity

0.4x

Promoter Holding

64.0%

12M Momentum

-43.9%

52-week range

₹26.95₹62.65

0% of the way from its 52-week low to its high

Price risk

1Y volatility

49.1%

Beta vs sector

1-year daily

0.52

Balance sheet & cash

Interest cover

operating profit ÷ interest

-3.5x

Cash from profit, 3Y

operating cash flow ÷ net profit

2.88x

Share count, 1Y

unchanged

What is the price implying?

Trailing earnings per share are negative, so a P/E-based figure does not exist. See the loss-makers list on the Expectations Gap page for a revenue-based version.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

What changed?

Oct '26Fell 71% from the Aug 2023 peak to the Oct 2026 low.
Jun '26EPS (TTM) turned negative.
Jun '26Slipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
Jun '26Dividend payout cut from 16% to 0% of profit.
Jun '25Year-on-year EPS growth turned negative.
Jun '25P/E crossed above the 90th percentile of its own history to date (18.4x).
Jun '25Slipped to the bottom quartile of Health Technology on EPS growth (from the 2nd quartile).
Jun '24Revenue (TTM) reached a new high of ₹200 cr.

Show 21 earlier events

Jun '24Started paying a dividend (payout 9% of profit).
Sep '23Slipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
Jun '23Year-on-year EPS growth turned positive.
Jun '23Moved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
Feb '23Regained the 2022-12 peak, 0 months after the low.
Feb '23Fell 28% from the Dec 2022 peak to the Feb 2023 low.
Nov '22Regained the 2022-04 peak, 4 months after the low.
Aug '22P/E crossed above the 90th percentile of its own history to date (11.2x).
Jul '22Fell 36% from the Apr 2022 peak to the Jul 2022 low.
Jun '22Moved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
Apr '22Regained the 2022-01 peak, 1 month after the low.
Apr '22P/E crossed above the 90th percentile of its own history to date (13.2x).
Mar '22Fell 42% from the Jan 2022 peak to the Mar 2022 low.
Jan '22Regained the 2021-05 peak, 4 months after the low.
Dec '21P/E crossed above the 90th percentile of its own history to date (10.2x).
Sep '21Fell 48% from the May 2021 peak to the Sep 2021 low.
Jun '21Slipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
May '21Regained the 2019-04 peak, 14 months after the low.
Jun '20Year-on-year EPS growth turned negative.
Jun '20Slipped to the 3rd quartile of Health Technology on EPS growth (from the top quartile).
Mar '20Fell 67% from the Apr 2019 peak to the Mar 2020 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Are profits backed by cash?

3 of 4 checks are within range, 1 near a threshold.
Tap a check to see how it is measured.

Other income reliance—Not enough data

Not enough reported data to compute this.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow4 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 4. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-42 daysWithin range

Debtor days are below the median of the previous three fiscal years by 42 days (25 vs 67). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress45% of fixed assetsNear threshold

Capital work-in-progress is 45% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+9 days / 2 yrsWithin range

Days payable changed by +9 over two years. Bands: rise of up to 30 days; more than 30 days.

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 2 years, promoters added 0.7 pts.
The number of shareholders rose from 397 to 639 (+61%) between Mar 2020 and Mar 2026.

Holdings, Mar '26

How each group changed

GroupMar '20Mar '26Change

Promoters62.3%64.0%+1.7 pts

FIIs0.0%0.0%0.0 pts

DIIs1.9%0.0%-1.9 pts

Public and others35.8%35.0%-0.9 pts

Number of shareholders

639shareholders+61% since Mar '20

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

How rough has the ride been?

Maximum drawdown-70.6%not yet recovered

1-year volatility49.1%annualised

Monthly share price

Last 90 trading days

Drawdown from peak

Largest drawdowns

-70.6% (2023-08 peak to 2026-10 low, not yet recovered)

-66.9% (2019-04 peak to 2020-03 low, recovered 2021-05)

-47.9% (2021-05 peak to 2021-09 low, recovered 2022-01)

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

ROCE

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Nov '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Oct '26

Lower rank Higher rank

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What happened next to similar setups

+11.1%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like MOHINI HEALTH AND HYGIENE LTD today on valuation, return on capital, debt, growth, price momentum and size.
Over the following 12 months the middle half of them returned −12% to +68% vs the market, against −1% for all non-financial companies in the same months.
The gap against the base rate (+11.8%, 80% range −0.7% to +19.6%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 9 beyond the range shown, drawn at the edge

Similar setups' median

+11.1%

All companies' median

−0.7%

Beat the market

60% vs 49%

50 past situations · 50 companies · 26 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ASTRON Process Industries	Oct 2023	—	-9%	−19%	−30%	−47%
GILLANDERS Consumer Non-Durables	Oct 2024	—	-8%	+3%	−42%	+34%
PEARLPOLY Process Industries	Apr 2021	—	-14%	+26%	−29%	+44%
NITCO Producer Manufacturing	Sep 2023	—	-11%	−17%	−37%	+207%
AKSHAR Process Industries	Sep 2023	—	-4%	−12%	−44%	−68%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
AGROPHOS Process Industries	Aug 2024	—	—	+12%	−27%	+10%
INDTERRAIN Consumer Non-Durables	Sep 2025	—	-5%	−42%	−44%	−11%
CCHHL Consumer Services	Mar 2020	—	0%	−73%	−76%	+27%

How reliable is this?

Matched on P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high and size. Closest on: 12-month momentum, ROCE and drawdown from 12-month high. Not used (unavailable for this company): P/E, operating margin and volatility. This company is loss-making, so it was only compared with loss-making companies. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to MOHINI HEALTH AND HYGIENE LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-10-30. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 97,430 company-months from 2000 companies; financial: 5,632 company-months from 106 companies. 2240 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Monthly history (93 months)

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-10	—	₹144 cr	-18.9%	-4.0%	0.4x
2026-09	—	₹144 cr	-19.3%	-4.0%	0.4x
2026-08	—	₹144 cr	-19.3%	-4.0%	0.4x
2026-07	—	₹144 cr	-19.3%	-4.0%	0.4x
2026-06	—	₹144 cr	-19.3%	-4.0%	0.4x
2026-05	12.1x	₹168 cr	5.7%	14.0%	0.3x
2026-04	12.1x	₹168 cr	5.7%	14.0%	0.3x
2026-03	11.4x	₹168 cr	5.7%	14.0%	0.3x
2026-02	12.4x	₹168 cr	5.7%	14.0%	0.3x
2026-01	11.2x	₹168 cr	5.7%	14.0%	0.3x
2025-12	12.2x	₹168 cr	5.7%	14.0%	0.3x
2025-11	13.0x	₹168 cr	5.7%	14.0%	0.3x
2025-10	15.0x	₹168 cr	5.7%	14.0%	0.3x
2025-09	16.3x	₹168 cr	5.7%	14.0%	0.3x
2025-08	16.8x	₹168 cr	5.7%	14.0%	0.3x
2025-07	16.9x	₹168 cr	5.7%	14.0%	0.3x
2025-06	18.4x	₹168 cr	5.7%	14.0%	0.3x
2025-05	10.2x	₹200 cr	11.0%	14.0%	0.2x
2025-04	9.9x	₹200 cr	11.0%	14.0%	0.2x
2025-03	10.3x	₹200 cr	11.0%	14.0%	0.2x
2025-02	10.3x	₹200 cr	11.0%	14.0%	0.2x
2025-01	10.5x	₹200 cr	11.0%	14.0%	0.2x
2024-12	8.8x	₹200 cr	11.0%	14.0%	0.2x
2024-11	8.5x	₹200 cr	11.0%	14.0%	0.2x
2024-10	9.0x	₹200 cr	11.0%	14.0%	0.2x
2024-09	10.1x	₹200 cr	11.0%	14.0%	0.2x
2024-08	9.9x	₹200 cr	11.0%	14.0%	0.2x
2024-07	9.7x	₹200 cr	11.0%	14.0%	0.2x
2024-06	10.3x	₹200 cr	11.0%	14.0%	0.2x
2024-05	16.1x	₹192 cr	7.9%	12.0%	0.3x
2024-04	15.1x	₹192 cr	7.9%	12.0%	0.3x
2024-03	14.2x	₹192 cr	7.9%	12.0%	0.3x
2024-02	15.7x	₹192 cr	7.9%	12.0%	0.3x
2024-01	18.7x	₹192 cr	7.9%	12.0%	0.3x
2023-12	18.1x	₹192 cr	7.9%	12.0%	0.3x
2023-11	19.1x	₹192 cr	7.9%	12.0%	0.3x
2023-10	21.8x	₹192 cr	7.9%	12.0%	0.3x
2023-09	19.0x	₹192 cr	7.9%	12.0%	0.3x
2023-08	24.7x	₹192 cr	7.9%	12.0%	0.3x
2023-07	16.5x	₹192 cr	7.9%	12.0%	0.3x
2023-06	17.4x	₹192 cr	7.9%	12.0%	0.3x
2023-05	17.0x	₹136 cr	7.2%	10.0%	0.5x
2023-04	16.3x	₹136 cr	7.2%	10.0%	0.5x
2023-03	16.0x	₹136 cr	7.2%	10.0%	0.5x
2023-02	15.7x	₹136 cr	7.2%	10.0%	0.5x
2023-01	14.4x	₹136 cr	7.2%	10.0%	0.5x
2022-12	14.1x	₹136 cr	7.2%	10.0%	0.5x
2022-11	17.1x	₹136 cr	7.2%	10.0%	0.5x
2022-10	11.9x	₹136 cr	7.2%	10.0%	0.5x
2022-09	11.4x	₹136 cr	7.2%	10.0%	0.5x
2022-08	11.2x	₹136 cr	7.2%	10.0%	0.5x
2022-07	10.1x	₹136 cr	7.2%	10.0%	0.5x
2022-06	11.0x	₹136 cr	7.2%	10.0%	0.5x
2022-05	11.2x	₹137 cr	7.8%	11.0%	0.6x
2022-04	13.2x	₹137 cr	7.8%	11.0%	0.6x
2022-03	8.5x	₹137 cr	7.8%	11.0%	0.6x
2022-02	7.1x	₹137 cr	7.8%	11.0%	0.6x
2022-01	9.2x	₹137 cr	7.8%	11.0%	0.6x
2021-12	10.2x	₹137 cr	7.8%	11.0%	0.6x
2021-11	7.5x	₹137 cr	7.8%	11.0%	0.6x
2021-10	6.5x	₹137 cr	7.8%	11.0%	0.6x
2021-09	6.5x	₹137 cr	7.8%	11.0%	0.6x
2021-08	7.1x	₹137 cr	7.8%	11.0%	0.6x
2021-07	8.3x	₹137 cr	7.8%	11.0%	0.6x
2021-06	7.7x	₹137 cr	7.8%	11.0%	0.6x
2021-05	7.3x	₹129 cr	9.7%	11.0%	0.5x
2021-04	6.7x	₹129 cr	9.7%	11.0%	0.5x
2021-03	6.7x	₹129 cr	9.7%	11.0%	0.5x
2021-02	5.8x	₹129 cr	9.7%	11.0%	0.5x
2021-01	6.0x	₹129 cr	9.7%	11.0%	0.5x
2020-12	5.9x	₹129 cr	9.7%	11.0%	0.5x
2020-11	5.0x	₹129 cr	9.7%	11.0%	0.5x
2020-10	4.5x	₹129 cr	9.7%	11.0%	0.5x
2020-09	5.0x	₹129 cr	9.7%	11.0%	0.5x
2020-08	5.0x	₹129 cr	9.7%	11.0%	0.5x
2020-07	4.2x	₹129 cr	9.7%	11.0%	0.5x
2020-06	4.4x	₹129 cr	9.7%	11.0%	0.5x
2020-05	4.4x	₹147 cr	10.6%	14.0%	0.7x
2020-04	4.2x	₹147 cr	10.6%	14.0%	0.7x
2020-03	2.8x	₹147 cr	10.6%	14.0%	0.7x
2020-02	3.9x	₹147 cr	10.6%	14.0%	0.7x
2020-01	5.3x	₹147 cr	10.6%	14.0%	0.7x
2019-12	4.1x	₹147 cr	10.6%	14.0%	0.7x
2019-11	4.4x	₹147 cr	10.6%	14.0%	0.7x
2019-10	4.3x	₹147 cr	10.6%	14.0%	0.7x
2019-09	4.0x	₹147 cr	10.6%	14.0%	0.7x
2019-08	4.1x	₹147 cr	10.6%	14.0%	0.7x
2019-07	3.7x	₹147 cr	10.6%	14.0%	0.7x
2019-06	4.7x	₹147 cr	10.6%	14.0%	0.7x
2019-05	8.4x	₹169 cr	8.6%	—	0.9x
2019-04	9.6x	₹169 cr	8.6%	—	0.9x
2019-03	12.4x	₹169 cr	8.6%	—	0.9x
2019-02	8.4x	₹169 cr	8.6%	—	0.9x

Methodology and data notes